KYMR Stock Price | Kymera Therapeutics Inc P/E, Revenue, EPS, & Forecasts

Kymera Therapeutics Inc • KYMR

Capital at risk.

About
Metrics
Forecasts
Earnings performance
Financial performance
Sentiment analysis
FAQs

About Kymera Therapeutics Inc

Ticker

KYMR

Trading on

NASDAQ

ISIN

US5015751044

Industry

Biotechnology

Sector

Healthcare

CEO

Dr. Nello Mainolfi M.D., Ph.D.

Headquarters

500 North Beacon Street, Watertown, MA, United States, 02472

Employees

225

Website

kymeratx.com

Kymera Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa and atopic dermatitis. The company also develops STAT6, a type 2 inflammation in allergic and atopic diseases; and TYK2 to treat autoimmune and inflammatory diseases. The company has a strategic alliance with Sanofi S.A. for the development of drug candidates targeting IRAK4 outside of the oncology and immuno-oncology fields. Kymera Therapeutics, Inc. was incorporated in 2015 and is headquartered in Watertown, Massachusetts.

Metrics

BasicAdvanced

Market cap

$4.22B

P/E ratio

EPS

-$3.60

Dividend Yield

0.00%

Beta

2.3

Forward P/E ratio

EBIDTA

$-322M

Ex dividend date

Price & volume

Market cap

$4.22B

Average daily volume

0.7M

90-day return

30-day return

7-day return

Dividends

Dividend per share

$0.00

Dividend yield

0.00%

Forward dividend per share

$0.00

Forward dividend yield

0.00%

Payout ratio

0.00%

Valuation

P/E ratio

Forward P/E

PEG ratio

Trailing P/E

Price to sales

96.5

Price to book

4.12

Earnings

EPS

-$3.60

EPS estimate (current quarter)

-$0.79

EPS estimate (next quarter)

-$0.89

EBITDA

$-322M

Revenues (TTM)

$43.7M

Revenues per share (TTM)

$0.53

Technicals

Beta

2.3

52-week High

$63.96

52-week Low

$19.45

50-day moving average

$54.19

200-day moving average

$41.42

Short ratio

9.05

Short %

14.01%

Management effectiveness

ROE (TTM)

-32.09%

ROA (TTM)

-19.21%

Profit margin

0.00%

Gross profit margin

$-261M

Operating margin

-3,207.89%

Growth

Quarterly earnings growth (YoY)

0.00%

Quarterly revenue growth (YoY)

-26.10%

Share stats

Outstanding Shares

71.9M

Float

47.4M

Insiders %

2.50%

Institutions %

111.79%

Analyst Insights & forecasts

85% Buy

15% Hold

0% Sell

Based on information from 20 analysts.

Average price target

$73.82

Earnings per share (EPS) forecast

windowbar_chart_4_bars

Actual

Expected

Surprise

-$0.89

-$0.79

-12.92%

Q4 • 24Missed

-$0.82

-$0.73

-12.33%

Q1 • 25Missed

-$0.95

-$0.83

-14.46%

Q2 • 25Current

QuarterlyAnnual

Financial Performance

windowbar_chart_4_bars

Income StatementBalance SheetCash Flow

windowbar_chart_4_bars

Revenue

Net income

Profit margin

$11.5M

$-76.6M

-667.60%

Q2 • 25

$2.8M

$-82.2M

-2,973.05%

Q3 • 25

-75.91%

7.26%

345.33%

QoQ growth

QuarterlyAnnual

Totals assets

Total liabilities

Debt to assets

$1.13B

$160M

14.11%

Q2 • 25

$1.1B

$156M

14.14%

Q3 • 25

-2.57%

-2.38%

0.19%

QoQ growth

QuarterlyAnnual

Operating

Investing

Financing

Free cash flow

$-59.9M

$60M

$246M

$-60.6M

Q2 • 25

$-27.1M

$39.5M

$-27.3M

Q3 • 25

-54.73%

-83.92%

-54.95%

QoQ growth

QuarterlyAnnual

Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Past performance is no guarantee of future results. Your return may be affected by currency fluctuations and applicable fees and charges. The value of your investment may go up as well as down. When investing, your capital at risk.

Build your future fund today!

Automate your wealth-building journey and turn investing into a habit that your future self will be grateful for!

Capital at risk.

FAQs

How much is a Kymera Therapeutics Inc share?

Kymera Therapeutics Inc shares are currently traded for undefined per share.

How many shares does Kymera Therapeutics Inc have?

Kymera Therapeutics Inc currently has 71.9M shares.

Does Kymera Therapeutics Inc pay dividends?

No, Kymera Therapeutics Inc doesn't pay dividends.

What is Kymera Therapeutics Inc 52 week high?

Kymera Therapeutics Inc 52 week high is $63.96.

What is Kymera Therapeutics Inc 52 week low?

Kymera Therapeutics Inc 52 week low is $19.45.

What is the 200-day moving average of Kymera Therapeutics Inc?

Kymera Therapeutics Inc 200-day moving average is $41.42.

Who is Kymera Therapeutics Inc CEO?

The CEO of Kymera Therapeutics Inc is Dr. Nello Mainolfi M.D., Ph.D..

How many employees Kymera Therapeutics Inc has?

Kymera Therapeutics Inc has 225 employees.

What is the market cap of Kymera Therapeutics Inc?

The market cap of Kymera Therapeutics Inc is $4.22B.

What is the P/E of Kymera Therapeutics Inc?

The current P/E of Kymera Therapeutics Inc is null.

What is the EPS of Kymera Therapeutics Inc?

The EPS of Kymera Therapeutics Inc is -$3.60.

What is the PEG Ratio of Kymera Therapeutics Inc?

The PEG Ratio of Kymera Therapeutics Inc is null.

What do analysts say about Kymera Therapeutics Inc?

According to the analysts Kymera Therapeutics Inc is considered a buy.